Nav: Home

Walter Reed Army Institute of Research begins phase 2 clinical trial of Ebola vaccine

January 06, 2016

SILVER SPRING, Md. - The Walter Reed Army Institute of Research (WRAIR) today announced the initiation of a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime-boost Ebola vaccine regimen in both healthy and HIV-infected study volunteers.

This study includes two vaccine candidates, Ad26.ZEBOV from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and MVA-BN-Filo from Bavarian Nordic, which will be given sequentially as a "prime boost" regimen. Seventy-five volunteers will receive a prime dose with MVA-BN-Filo followed by a boost with Ad26.ZEBOV at the WRAIR Clinical Trials Center in Silver Spring, Md. Early next year, WRAIR-affiliated sites in Africa will also begin evaluating this regimen, as well as a vaccination schedule beginning with Ad26.ZEBOV and then boosted with MVA-BN-Filo.

Researchers will assess the safety and tolerability of the vaccine schedules and characterize the immune response, which should help them better understand these different regimens. Janssen and other development partners have generated preliminary data from a small group of healthy subjects demonstrating that both regimens were safe and immunogenic.

The study will strengthen safety and immunogenicity evidence of the regimens in healthy subjects and extend the population studied in Phase 1 to include volunteers up to and including 70 years of age and volunteers with stably suppressed HIV-infection.

"It is critical that we know these vaccines are safe and immunogenic in the communities where they will be used in Africa," said Lt. Col. Julie Ake, an infectious disease physician, U.S. Military HIV Research Program (MHRP) Principal Deputy and protocol chair for the international study.

The study includes HIV-infected volunteers because they represent some of those who might benefit from a preventive Ebola vaccine in Africa. "It's an important consideration given that both of these viruses can be present in the same communities," said Col. Nelson Michael, MHRP Director.

This clinical trial is a collaboration between WRAIR and Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, with funding from the Joint Vaccines Acquisition Program at the Department of Defense's Joint Program Executive Office for Chemical and Biological Defense.

Initially conducted at WRAIR in Silver Spring, Md., the study will expand to six sites in Africa in early 2016. Approximately 575 volunteers will participate in total. It will be conducted at clinical research sites affiliated with WRAIR's Military HIV Research Program in Nigeria, Uganda, Kenya, Tanzania and Mozambique.

This is the second Ebola vaccine clinical trial conducted at WRAIR, and will be the fourth Ebola vaccine study conducted in Africa by the Institute and MHRP.

"Infectious diseases such as Ebola pose a significant threat to the U.S. Military and the global community," said Col. Stephen Thomas, WRAIR's Deputy Commander of Operations. "WRAIR has extensive expertise in infectious diseases and an international research network in countries where diseases are endemic, giving us an ideal platform to conduct these types of studies."
About the candidate Ebola vaccines

Ad26.ZEBOV is a monovalent vaccine expressing the full length Ebola virus (EBOV) Mayinga glycoprotein (GP). MVA-BN-Filo is a multivalent vaccine expressing the EBOV GP, Sudan virus (SUDV) GP, Marburg virus (MARV) GP, and the Tai Forest virus nucleoprotein.

Janssen's investigational Ebola vaccine regimen was discovered in a collaborative research program with the National Institutes of Health (NIH). This program received direct funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, under Contract Numbers HHSN272200800056C, and HHSN272201000006I and HHSN272201200003I, respectively. In January 2015, the Innovative Medicines Initiative (IMI) awarded a consortia of leading global research institutions and non-government organizations working in conjunction with the Janssen Pharmaceutical Companies grants totaling more than €100 million from the Ebola+ programme to support the development, manufacturing and deployment of the vaccine regimen. In September 2015, Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, was awarded $28.5 million from The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to help accelerate the development of its investigational Ebola prime-boost vaccine regimen.

About the Walter Reed Army Institute of Research

Headquartered in Silver Spring, Maryland, and established in 1893, the Walter Reed Army Institute of Research (WRAIR) is the oldest, largest, and most diverse military research institute of the U.S. Army Medical Research and Materiel Command and Department of Defense. With extensive research units in Africa, Asia and the Caucasus Region, WRAIR is comprised of two Centers of Excellence, the Center for Infectious Disease Research and the Center for Military Psychiatry and Neuroscience.

The U.S. Military HIV Research Program (MHRP)

Related Clinical Trial Articles:

Landmark clinical trial to help juvenile idiopathic arthritis sufferers
A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.
Clinical trial for new innovative osteoarthritis drug
The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis.
New malaria vaccine effective in clinical trial
University of Tuebingen researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine.
Clinical trial of infection detecting bandages begins
A clinical trial of a smart bandage which changes color when it detects infections is beginning using samples from burns patients from four UK hospitals.
First human clinical trial for nicotinamide riboside
In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage.
More Clinical Trial News and Clinical Trial Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...